Introduction: Elevated serum troponin levels are a reliable indicator of right ventricular wall stress in patients with acute pulmonary artery embolism (PE). Raised troponin levels have been shown to predict adverse clinical outcome in these individuals. In this context it was our aim to determine the additional role of the heart-type fatty acid-binding protein (H-FABP) in patients with acute PE.
Introduction
Despite recent advances in diagnosis and treatment, assessment of risk and appropriate management of patients with acute pulmonary embolism (PE) remain difficult due to the variability of clinical presentation and degree of hemodynamic instability [1, 2] . Recent studies focussed on a better definition of patients at higher risk in whom the use of a more aggressive therapy (e.g. thrombolysis) might confer clinical benefit.
Echocardiography plays an important role in the diagnosis and risk stratification of PE, showing that right ventricular dysfunction strongly correlates with in-hospital mortality [3, 4] . But echocardiography may not be available anytime; therefore the attention was drawn to the more easily available serum measurement of biomarkers. Recently, it has been proposed that the degree of right ventricular wall stress with consecutive release of cellular proteins from injured cadiomyocytes correlates with the clinical impairment and with mortality in patients with PE. Of the proposed biomarkers, troponin I and troponin T have been shown to correlate with right ventricular dysfunction and moreover with in hospital mortality. Moreover, elevated troponin levels predicted a complicated in-hospital course of patients with PE, as compared to other biomarkers such as CKMB, D-Dimers or NT-Pro-BNP [5, 6] .
Lately, several studies reported that heart-type fatty acid binding protein (H-FABP), a novel low molecular weight cytosolic protein, enables earlier and precise diagnosis and risk assessment in patients with acute coronary syndromes as compared to other biomarkers [7, 8] . Recent data could even demonstrate an association of elevated levels of H-FABP with increased risk of death and major cardiac events in this setting, thus having important prognostic power [9] .
There are only few data regarding the diagnostic and prognostic value of H-FABP in patients presenting with PE [10, 11] . It was therefore our aim to assess the prognostic value of H-FABP in acute pulmonary embolism and to correlate it to other established biomarkers such as troponin I and to echocardiographic data. To detect right ventricular overload, the following parameters were determined as described previously in detail [13] : Briefly, dilatation of the right ventricle was defined when end-diastolic diameter was greater than 30mm from the parasternal view; the RV/LV-ratio was defined abnormal when greater than 0,6 [10] . Another recent trial reported an RV/LV-ratio >0,78 as a cut-off [14] . In the recently published guidelines of the European Society of Cardiology a cut-off value >1 was suggested [12] . Parameters for detecting right ventricular overload and dysfunction were a right ventricular end systolic pressure >35mmHg, the grade of tricuspid regurgitation, the presence of a paradoxical septal movement, a tricuspid annular plane systolic excursion (TAPSE) <20mm and the presence of typical wall motion with normokinesia of the apical segment, akinesia of the free mid-wall and abnormal wall motion of the base segment, also known as the McConnell sign [15] . After measuring all these parameters, visual estimate of RV-function and the modified Simpson's method for estimation of RV ejection fraction was performed [16] . An impaired right ventricle was defined when RV ejection fraction was <45% according to a recent report [17] .
Methods

Study population and design
Biochemical analyses
On admission, blood samples were obtained prior The abovementioned reasons illustrate that there is still the need for better tools to enable precise risk stratification and thereby permitting early therapeutic and potentially life-saving decisions. This is the reason why our attention was drawn to H-FABP, a biomarker that has gained increasing importance because of its specificity for myocardial damage and its early release. It is considered to be equal or superior to CK, CK-MB, cardiac troponins and myoglobin in the detection of myocardial injury and diagnosis for unstable coronary artery disease [21] . Furthermore, elevation of H-FABP is associated with an increased risk of death and major cardiac events in coronary patients [7, 21, 22] . Being a small soluble protein, which is abundantly present in the cytoplasm of cardiomyocytes, it rises earlier than the other biomarkers after the onset of sarcolemmal injury [7] .
In our study, many patients with confirmed PE had normal H-FABP-levels suggesting that this parameter is not suitable for the diagnosis of PE. But in view of our data it proved to be a very reliable marker in the prognostic assessment of this study population. This is in accordance with recent reports, where, compared to troponin or N-terminal pro-brain natriuretic peptide, H-FABP was the only biomarker reliably predicting an adverse outcome [11] . Collectively, there is accumulating evidence that H-FABP may become an important tool for the management of patients with PE. In regard to echocardiographic findings it has been previously shown that right ventricular dysfunction is as an independent predictor of early mortality in PE. This seems true not only in patients presenting with arterial hypotension and cardiogenic shock, but also in normotensive patients [3, 4, 11, 20] . In the reported studies, Although being a small study, it showed a great potential benefit in identifying patients at greater risk which should be evaluated further in bigger studies.
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